Introduction: The 21-gene Oncotype DX Breast Recurrence Score® test, (Genomic Health, Redwood City CA) has not been formally evaluated in an older cohort with estrogen receptor (ER)-positive breast cancer (BC) in term of physicians' treatment decisions. We determine the utility of Recurrence Score® (RS) result on adjuvant therapy prescription in elderly patients with resected early BC.
Material And Methods: PONDx was a multicenter, prospective, observational study, and which investigated the real-life use of the Oncotype DX® test by physicians treating early BC patients in clinical practice.
Results: Data from the elderly extracted from 1724 BC patients who underwent Oncotype DX testing were available from 27 reference centers located in 6 regions of Italy (Lombardia, Lazio, Emilia Romagna, Campania, Abruzzo, and Marche). A total of 230 patients (13% of the total population) aged > 70 years were analyzed. The study primarily evaluated the impact of the Oncotype DX test on adjuvant treatment decisions. Physicians chosen chemotherapy plus endocrine therapy in 36% of elderly patients and 46% of those 50-70 years before the Oncotype DX test. After knowing the RS data, these rates fell to 23 and 33% (38 and 28% relative reduction, respectively).
Conclusions: 21-gene test may be helpful even in a relatively low-risk group as elderly patients and may avoid the toxicity of adjuvant chemotherapy in a significant amount. If the Oncotype DX test is currently adopted on a large scale among the elderly and may impact the general prognosis of elderly BC patients, it is challenging and still unproven.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10549-021-06464-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integration of Genomic Tests in Prostate Cancer Care: Implications for Clinical Practice and Patient Outcomes.
Curr Issues Mol Biol
December 2024
First Department of Urology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Prostate cancer (PCa) is a common malignancy in men and is among the leading causes of cancer-related death worldwide. Genomic tests assess disease aggressiveness and guide treatment, particularly in low- and intermediate-risk PCa. We reviewed the literature on the use of four genomic tests (Prolaris, Promark, Oncotype DX, and Decipher) in assessing the prognosis of PCa and their use in treatment decision-making.
View Article and Find Full Text PDFChallenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score test.
Diagnosis (Berl)
December 2024
Sarah Cannon Research Institute, Nashville, TN, USA.
Article Synopsis
- Personalized medicine in oncology has great potential, but its adoption in Europe is hindered by various challenges, as seen with the Oncotype DX Breast Recurrence Score assay.
- The case study details obstacles faced in integrating this genomic test into European healthcare from 2004 to 2018, including issues with clinical evidence, reimbursement, and regulatory processes.
- Key findings from the TAILORx study suggest that, for certain breast cancer patients, endocrine therapy may suffice without the need for additional adjuvant chemotherapy, highlighting the importance of personalized treatment approaches.
Article Synopsis
- - The RSClinN+ tool was developed to better predict recurrence risk and the benefits of chemotherapy specifically for patients with HR+/HER2-negative, lymph node-positive breast cancer, by incorporating both the Oncotype DX score and other clinical factors like tumor size and age.
- - Analysis of data from over 5,000 patients revealed that RSClinN+ offered significantly improved prognostic accuracy compared to using the Oncotype DX score alone or clinicopathological models, especially for premenopausal and postmenopausal women.
- - Validation of RSClinN+ showed that it effectively estimates prognosis and potential chemotherapy benefits, making it a valuable personalized tool for clinicians in managing breast cancer treatment decisions.
Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- breast cancer.
Ann Diagn Pathol
February 2025
Department of Breast and Thyroid Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. Electronic address:
Oncotype DX is the only multigene assay supported by the National Comprehensive Cancer Network (USA) with Level 1 evidence for use on node-negative and postmenopausal node-positive patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)-breast cancer to predict the prognosis and to estimate chemotherapy add-on effects. However, the test's high cost prevents its use in most cases. Therefore, we aimed to obtain an alternative recurrence score (RS) prediction formula using the optimal clinicopathological factors.
View Article and Find Full Text PDFER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.
Breast Cancer Res Treat
November 2024
Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
Purpose: To evaluate the association between the HER2 score as provided by the Oncotype DX Recurrence Score (RS) assay, tumor characteristics, and outcomes in early-stage, ER + HER2-negative breast cancer (BC).
Methods: All women insured by the Clalit Health Services, with early-stage, ER + HER2-negative BC who underwent RS testing between 2008 and 2011 were included. Patient/tumor characteristics and Kaplan-Meier estimates for distant recurrence-free survival (DRFS) and overall survival (OS) were compared by HER2 category, based on the HER2 score provided by the RS assay: lower HER2 score group representing the lower third of the HER2 score range (≤ 8.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!